224 related articles for article (PubMed ID: 36435834)
21. Polymorphonuclear MDSCs are enriched in the stroma and expanded in metastases of prostate cancer.
Wen J; Huang G; Liu S; Wan J; Wang X; Zhu Y; Kaliney W; Zhang C; Cheng L; Wen X; Lu X
J Pathol Clin Res; 2020 Jul; 6(3):171-177. PubMed ID: 32149481
[TBL] [Abstract][Full Text] [Related]
22. Myeloid IKKβ promotes antitumor immunity by modulating CCL11 and the innate immune response.
Yang J; Hawkins OE; Barham W; Gilchuk P; Boothby M; Ayers GD; Joyce S; Karin M; Yull FE; Richmond A
Cancer Res; 2014 Dec; 74(24):7274-84. PubMed ID: 25336190
[TBL] [Abstract][Full Text] [Related]
23. Oncogenic PIK3CA recruits myeloid-derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5-lipoxygenase-dependent arachidonic acid pathway.
Li X; Chen G; Wang F; Guo X; Zhang R; Liu P; Dong L; Yu W; Wang H; Wang H; Yu J
Clin Transl Med; 2023 Nov; 13(11):e1483. PubMed ID: 37965796
[TBL] [Abstract][Full Text] [Related]
24. ARID1A mutations in cancer development: mechanism and therapy.
Zhang X; Zhang Y; Zhao J; Wu Y; Zhang N; Shen W
Carcinogenesis; 2023 May; 44(3):197-208. PubMed ID: 36882165
[TBL] [Abstract][Full Text] [Related]
25. Receptor-Interacting Protein Kinase 3 Deficiency Recruits Myeloid-Derived Suppressor Cells to Hepatocellular Carcinoma Through the Chemokine (C-X-C Motif) Ligand 1-Chemokine (C-X-C Motif) Receptor 2 Axis.
Li YM; Liu ZY; Wang JC; Yu JM; Li ZC; Yang HJ; Tang J; Chen ZN
Hepatology; 2019 Nov; 70(5):1564-1581. PubMed ID: 31021443
[TBL] [Abstract][Full Text] [Related]
26. Potentiation of inflammatory CXCL8 signalling sustains cell survival in PTEN-deficient prostate carcinoma.
Maxwell PJ; Coulter J; Walker SM; McKechnie M; Neisen J; McCabe N; Kennedy RD; Salto-Tellez M; Albanese C; Waugh DJ
Eur Urol; 2013 Aug; 64(2):177-88. PubMed ID: 22939387
[TBL] [Abstract][Full Text] [Related]
27. Differential Targeting of Gr-MDSCs, T Cells and Prostate Cancer Cells by Dactolisib and Dasatinib.
Liu G; Jin Z; Lu X
Int J Mol Sci; 2020 Mar; 21(7):. PubMed ID: 32230980
[TBL] [Abstract][Full Text] [Related]
28. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Highfill SL; Cui Y; Giles AJ; Smith JP; Zhang H; Morse E; Kaplan RN; Mackall CL
Sci Transl Med; 2014 May; 6(237):237ra67. PubMed ID: 24848257
[TBL] [Abstract][Full Text] [Related]
29. Promotion of DNA repair by nuclear IKKβ phosphorylation of ATM in response to genotoxic stimuli.
Sakamoto K; Hikiba Y; Nakagawa H; Hirata Y; Hayakawa Y; Kinoshita H; Nakata W; Sakitani K; Takahashi R; Akanuma M; Kamata H; Maeda S
Oncogene; 2013 Apr; 32(14):1854-62. PubMed ID: 22614018
[TBL] [Abstract][Full Text] [Related]
30. ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells.
Sen M; Wang X; Hamdan FH; Rapp J; Eggert J; Kosinsky RL; Wegwitz F; Kutschat AP; Younesi FS; Gaedcke J; Grade M; Hessmann E; Papantonis A; Strӧbel P; Johnsen SA
Clin Epigenetics; 2019 Jun; 11(1):92. PubMed ID: 31217031
[TBL] [Abstract][Full Text] [Related]
31. ARID1A deficiency and immune checkpoint blockade therapy: From mechanisms to clinical application.
Hu G; Tu W; Yang L; Peng G; Yang L
Cancer Lett; 2020 Mar; 473():148-155. PubMed ID: 31911080
[TBL] [Abstract][Full Text] [Related]
32. MAP3K7-IKK Inflammatory Signaling Modulates AR Protein Degradation and Prostate Cancer Progression.
Huang Z; Tang B; Yang Y; Yang Z; Shi L; Bai Y; Yan B; Karnes RJ; Zhang J; Jimenez R; Wang L; Wei Q; Yang J; Xu W; Jia Z; Huang H
Cancer Res; 2021 Sep; 81(17):4471-4484. PubMed ID: 34158377
[TBL] [Abstract][Full Text] [Related]
33. LATS2 inhibits the activity of NF-κ B signaling by disrupting the interaction between TAK1 and IKKβ.
Yao F; Zhou W; Zhong C; Fang W
Tumour Biol; 2015 Sep; 36(10):7873-9. PubMed ID: 25946971
[TBL] [Abstract][Full Text] [Related]
34. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.
Karin M; Ben-Neriah Y
Annu Rev Immunol; 2000; 18():621-63. PubMed ID: 10837071
[TBL] [Abstract][Full Text] [Related]
35. Extracellular Hsp90 mediates an NF-κB dependent inflammatory stromal program: implications for the prostate tumor microenvironment.
Bohonowych JE; Hance MW; Nolan KD; Defee M; Parsons CH; Isaacs JS
Prostate; 2014 Apr; 74(4):395-407. PubMed ID: 24338924
[TBL] [Abstract][Full Text] [Related]
36. The SWI/SNF complex is a mechanoregulated inhibitor of YAP and TAZ.
Chang L; Azzolin L; Di Biagio D; Zanconato F; Battilana G; Lucon Xiccato R; Aragona M; Giulitti S; Panciera T; Gandin A; Sigismondo G; Krijgsveld J; Fassan M; Brusatin G; Cordenonsi M; Piccolo S
Nature; 2018 Nov; 563(7730):265-269. PubMed ID: 30401838
[TBL] [Abstract][Full Text] [Related]
37. Loss of the SWI/SNF-ATPase subunit members SMARCF1 (ARID1A), SMARCA2 (BRM), SMARCA4 (BRG1) and SMARCB1 (INI1) in oesophageal adenocarcinoma.
Schallenberg S; Bork J; Essakly A; Alakus H; Buettner R; Hillmer AM; Bruns C; Schroeder W; Zander T; Loeser H; Gebauer F; Quaas A
BMC Cancer; 2020 Jan; 20(1):12. PubMed ID: 31906887
[TBL] [Abstract][Full Text] [Related]
38. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
[TBL] [Abstract][Full Text] [Related]
39. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress.
Tomihara H; Carbone F; Perelli L; Huang JK; Soeung M; Rose JL; Robinson FS; Lissanu Deribe Y; Feng N; Takeda M; Inoue A; Poggetto ED; Deem AK; Maitra A; Msaouel P; Tannir NM; Draetta GF; Viale A; Heffernan TP; Bristow CA; Carugo A; Genovese G
Cancer Res; 2021 Jan; 81(2):332-343. PubMed ID: 33158812
[TBL] [Abstract][Full Text] [Related]
40. Comparing the frequency of CD33
Sanaei MJ; Taheri F; Heshmati M; Bashash D; Nazmabadi R; Mohammad-Alibeigi F; Nahid-Samiei M; Shirzad H; Bagheri N
Cell Biol Int; 2021 Oct; 45(10):2086-2095. PubMed ID: 34184811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
